Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 8

recruiting
3 987
countries
28
conditions
2 109

978 trials match your criteria

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine

Plasma cell myeloma

Recruiting

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Factor VIII deficiency+1

Recruiting

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa

Age-related macular degeneration

Recruiting

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Factor VIII deficiency

Recruiting

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab

Factor VIII deficiency

Recruiting

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Coagulation factor X level

Recruiting

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001

Chronic myeloid leukaemia

Recruiting

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Asciminib Hydrochloride

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.